CCL19 and neoplasm: CCL21 shares the same receptor (CCR7) with CCL19; however, the differential ability of CCL19 and CCL21 for desensitizing CCR7 (81) and/or the ability of CCL21 for binding other receptors like CXCR3 might cause the differential anti-tumor potency.